P540 Can we predict response to cyclosporine as second line therapy in patients with severe acute colitis of inflammatory bowel disease

the anti-TNFalfa antibody-treated group and the non-antiTNFalfa antibody-treated group. Results: Rutgeerts’ grade 4 was significantly associated with abdominal symptoms, when compared with Rutgeerts’ grades 0 3 (P< 0.0001). Endoscopic recurrence designated as Rutgeerts’ grades 2 4 was associated with non-use of 5-aminosalicylic acid (P= 0.021) and post-operative period (longer than 1.5 year, P= 0.013). Clinical recurrence designated as Rutgeerts’ grades 4 was associated with non-use of 5-aminosalicylic acid (P=0.048), post-operative period (longer than 1.5 year, P= 0.0002) and use of immunomodulators (P= 0.039). The patency of the anastomotic sites in the antiTNFalfa antibody-treated group was better than in the nonanti-TNFalfa antibody-treated group (P= 0.035). Conclusions: Non-use of IFX or 5-aminosalicylic acid and postoperative period was associated with recurrence of smallbowel anastomotic sites in patients with CD.